PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE

被引：0
|
作者：
Andre, F. [1 ]
Marinsek, N. [2 ]
Ricci, J. F. [3 ]
Etchberger, J. [2 ]
Degun, R. [2 ]
Benelli, G. [4 ]
Saletan, S. [5 ]
Jerusalem, G. [6 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Navigant Consulting Inc, London, England
[3] Wellmera AG, Basel, Switzerland
[4] Novartis Farma SpA, Saronno, VA, Italy
[5] Nova Pharmaceut Corp, E Hanover, NJ USA
[6] CHU Sart Tilman, B-4000 Liege, Belgium
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1252
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A419 / A419
页数：1
相关论文
共 50 条
  • [1] PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE
    Jerusalem, G.
    Marinsek, N.
    Ricci, J.
    Etchberger, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Andre, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 122 - 122
  • [2] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in Europe.
    Jerusalem, Guy Heinrich Maria
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Andre, Fabrice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [4] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    [J]. SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [6] Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission
    Shah, M.
    Hunter, N.
    Ensminger, J.
    Shinn, D.
    Cole, A. J.
    Quinn, H. E.
    Edelstein, D. L.
    Wang, C.
    Smith, K. L.
    Richardson, A. L.
    Cimino-Mathews, A.
    Wolff, A. C.
    Cravero, K.
    Park, B. H.
    Stearns, V.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [7] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024,
  • [8] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    [J]. FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [9] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
    Moy, B.
    Lebrun, F.
    Bellet, M.
    Chow, L.
    Lang, I.
    Xu, B.
    Badwe, R. A.
    Hershman, D. L.
    Leip, E.
    Bardy-Bouxin, N.
    Duvillie, L.
    Neven, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    [J]. SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
12345